Parkinson's and Neuropathic Pain Reviewed by NeuroPerspective
CARDIFF, Calif., May 6, 2015 /PRNewswire/ -- NI Research (NIR) has released the May/June issue of NeuroPerspective, which features comprehensive reviews of two major areas: Parkinson's and Neuropathic Pain.
Logo - http://photos.prnewswire.com/prnh/20150505/213986LOGO
Parkinson's is one of the major neurodegenerative disorders associated with aging, and while it does not approach the scale of Alzheimer's, approximately one million US patients suffer from PD. Current treatment options are purely symptomatic, and dopaminergic supplementation exacts a high long-term price in exchange for a few years of improved motor symptoms.
"It has become clear that PD is far more than just a disease of motor control areas: Cognitive deficits loom large as a major source of distress and disability. There are improvements on the symptom-relief theme that are late in clinical development and very likely to arrive; the same cannot be said of disease-modification, where many of the issues that have plagued Alzheimer's research are also impediments to disease-modification in PD--other than Parkinson's research has been less vulnerable to premature closure on the question of mechanism. But the questions of what therapeutic payload, delivered by which modality, to which anatomical locations, in what form and quantity, have yet to be definitively answered. But there has been a revival of neurotrophic research which, while facing all of these unknowns, may now be in a position to succeed after a history of frequent disappointments from 1995-2005. Novel targets, such as Gcase, are becoming more prominent and are receiving the funding they need to move ahead," said NeuroPerspective publisher Harry Tracy PhD.
Neuropathic pain is a highly heterogeneous disorder, which has numerous pharmacological treatment options available, none of which constitute anything more than a partial solution, providing incomplete relief to a subgroup of patients. The casualty rate in neuropathic programs over the past five years has been virtually identical to that in Alzheimer's: Many formerly promising novel mechanisms have turned into disappointments, but AT2 and Nav 1.7 antagonism have survived, and head the list of potential new avenues to neuropathic pain treatment.
The May/June issue also offers Company Reviews of MedGenesis Therapeutix and Cynapsus Therapeutics; discussion and commentary regarding recent events and topics, including NeuralStem's Phase II results in ALS; the limitations in Biogen's aducanumab results-thus-far; and more. Released as a 63 page pdf.
About NI Research
NI Research is the leading publisher of independent research on the neurotherapeutics industry, and has developed an unmatched information base regarding both publicly and privately held CNS companies. Since 1995, NeuroPerspective (formerly NeuroInvestment) has been the authoritative, independent, review of the neurotherapeutics area, providing critical analyses of therapeutics-in-development.
A one-year (1-5 user) subscription to NeuroPerspective is $2450. The May/June issue is also being made available for single-issue purchase; $400.
NI Research is also preparing the 2015-16 edition of NeuroLicensing, which will comprehensively review current licensing trends in the CNS area, and evaluate large and midsize pharma companies in terms of their licensing agendas and performance.
In addition to our publications, NI Research's Second Opinion service provides consultation to the pharma/biotech industry regarding licensing/development strategies.
Further information and online purchasing with immediate download are available at http://www.niresearch.com/onlinestore.html.
Contact: NI Research, P.O. Box 1028, Cardiff CA 92007; 760.753.6376, Email
Contact
Harry Tracy
760.753.6376
SOURCE NI Research
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article